Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inozyme Pharma

0.9794
+0.05996.51%
Volume:376.19K
Turnover:357.71K
Market Cap:62.92M
PE:-0.60
High:1.00
Open:0.9139
Low:0.8953
Close:0.9195
Loading ...

Inozyme Pharma Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Apr

Promising Potential of INZ-701 in Treating ENPP1 Deficiency Drives Buy Rating for Inozyme Pharma

TIPRANKS
·
10 Apr

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

GlobeNewswire
·
10 Apr

Inozyme Pharma Price Target Maintained With a $15.00/Share by Needham

Dow Jones
·
08 Apr

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
31 Mar

Inozyme Pharma Is Maintained at Buy by Needham

Dow Jones
·
11 Mar

Inozyme Pharma Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Mar

Inozyme Pharma Focuses on ENPP1 Deficiency Program

TIPRANKS
·
11 Mar

Analysts Offer Insights on Healthcare Companies: Inozyme Pharma (INZY) and Urogen Pharma (URGN)

TIPRANKS
·
11 Mar

Inozyme Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Mar

Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating

MT Newswires Live
·
10 Mar

Inozyme Pharma Inc : Wedbush Cuts Target Price to $7 From $12

THOMSON REUTERS
·
10 Mar

Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction

Benzinga
·
10 Mar

Inozyme Pharma Inc - Expects $1.8 Million Cost for Workforce Reduction

THOMSON REUTERS
·
10 Mar

Inozyme Pharma Inc - Cash and Cost Savings Expected to Support Operations Into Q1 2026

THOMSON REUTERS
·
10 Mar

Inozyme Pharma FY EPS USD -1.62

THOMSON REUTERS
·
10 Mar

Inozyme Pharma FY Operating Expenses USD 104.03 Million

THOMSON REUTERS
·
10 Mar

Press Release: Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Dow Jones
·
10 Mar

Inozyme Pharma Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
07 Mar

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
24 Feb